Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints

Inhibiting the immune checkpoint (ICP) PD-1 based on PD-L1 expression status has revolutionized the treatment of various cancers, yet its efficacy in anaplastic thyroid carcinoma (ATC) remains limited. The therapeutic response depends upon multiple factors, particularly the conduciveness of the tumo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine pathology 2024-12, Vol.35 (4), p.419-431
Hauptverfasser:	Boruah, Monikongkona, Agarwal, Shipra, Mir, Riyaz Ahmad, Choudhury, Saumitra Dey, Sikka, Kapil, Rastogi, Sameer, Damle, Nishikant, Sharma, Mehar C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over B7-H1 Antigen - metabolism CTLA-4 protein Cytotoxicity Effector cells Endocrinology Female Galectin-9 Hepatitis A Virus Cellular Receptor 2 - metabolism Humans Immune checkpoint Immune Checkpoint Inhibitors - therapeutic use Immunofluorescence Immunohistochemistry Lymphocytes Lymphocytes B Lymphocytes T Lymphocytes, Tumor-Infiltrating - immunology Male Medicine Medicine & Public Health Microenvironments Middle Aged Oncology Pathology PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Retrospective Studies T-Lymphocytes, Cytotoxic - immunology Therapeutic targets Thyroid cancer Thyroid carcinoma Thyroid Carcinoma, Anaplastic - drug therapy Thyroid Carcinoma, Anaplastic - immunology Thyroid Carcinoma, Anaplastic - pathology Thyroid gland Thyroid Neoplasms - drug therapy Thyroid Neoplasms - immunology Thyroid Neoplasms - pathology Tumor Microenvironment - immunology Tumor-infiltrating lymphocytes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!